Integrated BioPharma, Inc. has scheduled its 2026 Annual Meeting of Stockholders for November 30, 2026. This meeting is significant as it will allow shareholders to vote on important matters that could shape the company’s future.

The meeting will take place at 9:00 a.m. local time at the company’s executive offices located at 225 Long Avenue, Hillside, New Jersey. Among the key proposals to be voted on are the election of Class II directors for a three-year term, the adoption of the 2025 Equity Incentive Plan, and the ratification of the appointment of CBIZ CPAs P.C. as the independent auditor for the fiscal year ending June 30, 2027.

Integrated BioPharma, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, is a smaller reporting company listed on the OTC exchange under the ticker INBP. The company has been actively engaging its shareholders and ensuring transparency through regular filings.

In the filing dated October 28, 2026, the company emphasized the importance of shareholder participation, urging stockholders to vote by proxy if they cannot attend the meeting in person. The notice also detailed that only holders of record as of October 15, 2026, are entitled to vote, with 31,059,610 shares outstanding on that date.

Shareholders will have the opportunity to influence the company's governance and strategic direction through their votes. The filing indicates that the board of directors unanimously recommends that stockholders vote in favor of the proposals presented at the meeting.

Looking ahead, the company will continue to keep its shareholders informed through proxy materials and its annual report, which will be available online. The outcome of the meeting could significantly impact Integrated BioPharma’s operational strategies and shareholder relations moving forward.